Publication | Open Access

European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme

Neuro-oncologyGliomaMedicineCancer ManagementRecurrent Glioblastoma MultiformePharmacologyPharmacotherapy60-Minute InfusionHigh-grade GliomasEuropean OrganizationCancer TreatmentAnti-cancer AgentOncologyRadiation OncologyCancer Research